Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast
Lipella Pharmaceuticals (Nasdaq: LIPO) announced that Co-Founder and Chief Medical Officer Dr. Michael Chancellor is featured in the latest episode of The Pharmaverse Podcast. The episode, titled 'From Medicine to Biotech Innovation,' explores Dr. Chancellor's 40-year career transition from clinical medicine to biotech leadership.
During the podcast, Dr. Chancellor discusses Lipella's development, including challenges in clinical trials, fundraising, and the IPO process. The company recently reported positive Phase 2a results for LP-310 in February 2025, showing clinically meaningful reductions in pain, ulceration, and inflammation for patients with Oral Lichen Planus.
Lipella Pharmaceuticals (Nasdaq: LIPO) ha annunciato che il Co-Fondatore e Direttore Medico Dr. Michael Chancellor è presente nell'ultimo episodio del The Pharmaverse Podcast. L'episodio, intitolato 'Dalla Medicina all'Innovazione Biotech', esplora la transizione della carriera di 40 anni del Dr. Chancellor dalla medicina clinica alla leadership nel settore biotech.
Durante il podcast, il Dr. Chancellor discute dello sviluppo di Lipella, inclusi i problemi nei trial clinici, il fundraising e il processo di IPO. L'azienda ha recentemente riportato risultati positivi della Fase 2a per LP-310 a febbraio 2025, mostrando riduzioni clinicamente significative nel dolore, nell'ulcerazione e nell'infiammazione per i pazienti affetti da Lichen Planus Orale.
Lipella Pharmaceuticals (Nasdaq: LIPO) anunció que el cofundador y director médico, Dr. Michael Chancellor, aparece en el último episodio de The Pharmaverse Podcast. El episodio, titulado 'De la Medicina a la Innovación Biotech', explora la transición de 40 años de carrera del Dr. Chancellor de la medicina clínica al liderazgo en biotecnología.
Durante el podcast, el Dr. Chancellor discute el desarrollo de Lipella, incluidos los desafíos en los ensayos clínicos, la recaudación de fondos y el proceso de OPI. La compañía reportó recientemente resultados positivos de la Fase 2a para LP-310 en febrero de 2025, mostrando reducciones clínicamente significativas en el dolor, la ulceración y la inflamación para los pacientes con Lichen Planus Oral.
리펠라 제약 (Nasdaq: LIPO)는 공동 창립자이자 최고 의료 책임자인 마이클 챈슬러 박사가 The Pharmaverse Podcast의 최신 에피소드에 출연했다고 발표했습니다. '의학에서 생명공학 혁신으로'라는 제목의 에피소드는 챈슬러 박사가 임상 의학에서 생명공학 리더십으로의 40년 경력 전환을 탐구합니다.
팟캐스트에서 챈슬러 박사는 리펠라의 개발에 대해 논의하며, 임상 시험의 도전, 자금 조달 및 IPO 과정에 대해 이야기합니다. 회사는 최근 2025년 2월에 LP-310의 2a상 긍정적인 결과를 보고하며, 구강 라이켄 플라누스 환자에서 통증, 궤양 및 염증의 임상적으로 의미 있는 감소를 보여주었습니다.
Lipella Pharmaceuticals (Nasdaq: LIPO) a annoncé que le co-fondateur et directeur médical, Dr. Michael Chancellor, est présenté dans le dernier épisode du podcast The Pharmaverse. L'épisode, intitulé 'De la Médecine à l'Innovation Biotech', explore la transition de carrière de 40 ans du Dr. Chancellor de la médecine clinique à la direction dans le secteur de la biotechnologie.
Au cours du podcast, le Dr. Chancellor discute du développement de Lipella, y compris les défis des essais cliniques, le financement et le processus d'introduction en bourse. L'entreprise a récemment rapporté des résultats positifs de la Phase 2a pour LP-310 en février 2025, montrant des réductions cliniquement significatives de la douleur, des ulcérations et de l'inflammation chez les patients atteints de Lichen Planus Oral.
Lipella Pharmaceuticals (Nasdaq: LIPO) gab bekannt, dass der Mitbegründer und Chief Medical Officer Dr. Michael Chancellor in der neuesten Episode des The Pharmaverse Podcasts zu hören ist. Die Episode mit dem Titel 'Von der Medizin zur Biotech-Innovation' untersucht den 40-jährigen Karriereübergang von Dr. Chancellor von der klinischen Medizin zur Biotech-Führung.
Im Podcast spricht Dr. Chancellor über die Entwicklung von Lipella, einschließlich der Herausforderungen bei klinischen Studien, der Mittelbeschaffung und dem IPO-Prozess. Das Unternehmen berichtete kürzlich über positive Ergebnisse der Phase 2a für LP-310 im Februar 2025, die klinisch signifikante Reduktionen bei Schmerzen, Geschwüren und Entzündungen bei Patienten mit oralem Lichen planus zeigen.
- Positive Phase 2a clinical trial results for LP-310 showing efficacy in pain, ulceration, and inflammation reduction
- None.
Episode titled "From Medicine to Biotech Innovation" now available
PITTSBURGH, March 31, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced that Co-Founder and Chief Medical Officer Dr. Michael Chancellor is featured in the latest episode of The Pharmaverse Podcast, hosted by pharmaceutical industry executive recruiter Michael Pietrack.
The episode, titled “From Medicine to Biotech Innovation,” offers an inside look at Dr. Chancellor’s journey from clinical medicine to biotech leadership. In this candid conversation, he discusses how Lipella’s innovation was born out of unmet medical need, the complexities of navigating early-stage biotech, the challenges of clinical trials and fundraising, and the process of taking a company public.
Dr. Chancellor also shares leadership insights drawn from his 40-year career in medicine and drug development.
The Pharmaverse Podcast is a leadership-focused series that offers exclusive insights from executives across the pharmaceutical and biotech industries. Each episode features prominent voices sharing perspectives on career growth, industry trends, and leadership strategies.
Watch the episode: Pharmaverse Podcast – From Medicine to Biotech Innovation
In February 2025, Lipella reported positive topline Phase 2a results for its lead product candidate LP-310 in the treatment of Oral Lichen Planus. LP-310 demonstrated clinically meaningful reductions in pain, ulceration, and inflammation across all key metrics, reinforcing the Company’s commitment to addressing unmet needs in inflammatory mucosal diseases.
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at lipella.com and follow us on X and LinkedIn .
Forward-Looking Statements
This press release includes certain "forward-looking statements" which are not historical facts, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, the current clinical trial results for LP-310 and our other products general capital market risks, our ability to regain and maintain compliance with the listing standards of The Nasdaq Stock Market LLC, regional, national or global political, economic, business, competitive, market and regulatory conditions, our current liquidity position and the need to obtain additional financing to support ongoing operations, and other risks as more fully described in our filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax or investment advice and should consult with your own advisors as to the matters described herein, as applicable.
CONTACT
Jonathan Kaufman
Chief Executive Officer
Lipella Pharmaceuticals Inc.
Info@Lipella.com
1-412-894-1853
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
FAQ
What were the Phase 2a results for Lipella's LP-310 treatment in February 2025?
What is Lipella Pharmaceuticals' (LIPO) main product candidate?
What was discussed in Dr. Chancellor's Pharmaverse Podcast episode?
When did Lipella Pharmaceuticals report their latest clinical trial results for LP-310?
